Neos Therapeutics Sells Off Despite Latest FDA Approval

Neos Therapeutics is selling off, despite its latest approval from the Food and Drug Administration (FDA). Sell-off refers to the rapid selling of securities such as stocks, bonds, and commodities. This increase in supply leads to a decline in the value of the security.

Adzenys ER, the company’s product intended for treatment of Attention Deficit Hyperactivity Disorder (ADHD), was recently approved by the FDA. Despite this, shares have fallen 5.4%. The product is expected to be commercially available early in 2018.

Neos Therapeutics develops, manufactures, and commercializes innovative extended-release (XR) products using its proprietary extended-release . . .